|
Published by: Espicom Healthcare Intelligence
Published: Dec. 5, 2007 - 196 Pages
Table of Contents
- Foreword
- Executive Summary
- France
- Introduction
- Key Data Projections, 2007-2012
- Healthcare System
- Organisation
- Health Insurance System
- Health Expenditure
- Health Expenditure, 1995-2006 (Billion Euros)
- Medical Consumption by Service, 2000-2006 (Billion Euros)
- Spending Trends on Pharmaceuticals & Medical Products in the Ambulatory Sector, 1995-2005 (%)
- Medical Consumption by Source of Funding, 1995-2006 (%)
- Medical Consumption by Sector & Source of Funding, 2005 (%)
- Healthcare Infrastructure
- Hospital Resources
- Hospital Services, 1995-2005
- Public Hospitals by Type, 2004
- Private Hospitals by Type, 2005
- Private Hospitals by Status, 2004
- Hospital Beds & Day Places by Specialty & Sector, 2005
- Hospital Activity
- Hospital Activity, 2001-2005
- Hospital Activity by Specialty, 2005
- Patient Distribution by Most Frequent Diagnostic Groups in Public & Private Hospitals, 2004
- Inpatient Activity in Public Short-Stay Units by Major Diagnostic Groups, 2003
- Inpatient Activity in Private Short-Stay Units by Major Diagnostic Groups, 2003
- Ambulatory Resources
- Independent Practitioners by Type of Practice, 2002 (%)
- Medical Personnel
- Medical Personnel, 1995-2004
- Doctors by Specialty & Sector, 2001-2003
- Pharmaceutical Market Overview
- Size
- Summary of the French Pharmaceutical Market, 2007
- Projections
- Market Projections, 2007-2012
- Local Manufacturers
- Mergers & Acquisitions of French Pharmaceutical Companies, 1995-2007
- Pharmaceutical Companies Operating in France
- Generic Market
- Size
- Reimbursable Market by Patent Status, 2002-2006 (Million Euros)
- Reimbursable Market by Patent Status, 2002-2006 (%)
- Change in Reimbursable Market by Patent Status, 2002-2006 (%)
- Reimbursable Market by Patent Status, 2002-2006 (Million Units)
- Reimbursable Market by Patent Status, 2002-2006 (%)
- Change in Reimbursable Market by Patent Status, 2003-2006 (%)
- Reimbursable Market by Substitution, 2006
- Substitutable Market by Reimbursement Status, 2005-2006 (Million Euros)
- Subtitutable Market by Reimbursement Status, 2005-2006 (%)
- Projections
- Projected Generics Market, 2007-2012 (US$ Billion)
- Outlook
- Outcomes of the New Reference Pricing System
- Increasing Prescribing of Generics
- Generic Drugs to Reduce Health Expenditure by 912 Million Euros in 2006
- Trends in Generic Drug Consumption, 2003-2006
- France Transposes EU Pharmaceutical Directive
- Pharmacists Associations Agree New Generics Target for 2007
- Generics Penetration Objectives by Volume, 2006
- Generics Penetration Objectives by Volume, 2007
- SWOT
- SWOT Analysis of the French Generics Market, 2007
- Trade Association
- Members of GEMME, 2007
- Domestic Production
- Leading French Generic Producers, 2005-2006 (%)
- Local Manufacturers
- Arrow Génériques
- Biogaran
- Bouchara-Recordati
- EG-Labo
- EG-Labo’s Sales, 2002-2006 (Million Euros)
- EG-Labo’s Sales as % of Stada’s Sales, 2002-2006
- Merck Génériques
- Merck Génériques’ Financial Indicators, 2003-2006
- Ranbaxy
- Ranbaxy Pharmacie Génériques’ Sales, 2004-2006 (US$ Million)
- ratiopharm
- ratiopharm France’s Sales, 2004-2006 (Million Euros)
- Sandoz
- Sandoz France’s Sales, 2001-2006 (Million Euros)
- Teva
- Winthrop
- Wockhardt
- Zydus France
- Zydus France’s Sales, 2003-2005
- Regulatory Environment
- Registration
- Pricing & reimbursement
- Pricing
- Pricing of Reimbursable Medicines in the Retail Pharmacy Market
- Price Revisions
- Pricing Activity
- Drug Pricing Applications Submitted by Type, 2006
- Average Number of Days Taken to Process First-Time Registrations, 2006
- Pharmacy Margins
- Reference Pricing (TFR)
- Pricing of Hospital Medicines
- Reimbursement
- Distribution of the Pharmaceutical Market According to Reimbursement Rate, 2006
- Intellectual Property
- Leading Active Ingredients Coming off Patent, 2005-2007
- Supplementary Protection Certificates
- Generics in the French PPI Market
- PPIs on the French market, 2007
- Reimbursable Sales of PPPIs (Régime Générale), 2002-2006 (Million Euros)
- Reimbursable Sales of PPPIs (Régime Générale), 2002-2006 (%)
- Reimbursable Sales of PPPIs (Régime Générale), 2002-2006 (Million Units)
- Reimbursable Sales of PPPIs (Régime Générale), 2002-2006 (%)
- Reimbursable Sales of PPPIs (Régime Générale), 2002-2006 (Average Unit Price, Euros)
- Reimbursable Sales of PPIs by Patent Status (Régime Générale), 2004-2006 (Million Euros)
- Reimbursable Sales of PPIs by Patent Status (Régime Générale), 2004-2006 (Million Units)
- Omeprazole and esomeprazole
- Omeprazole Sales Data (Régime Générale), 2004-2006 (Million Euros)
- Omeprazole Sales Data (Régime Générale), 2004-2006 (Million Units)
- Esomeprazole & Omeprazole Sales Data (Régime Générale), 2002-2006 (Million Euros)
- Esomepraole & Omeprazole Sales Data (Régime Générale), 2002-2006 (Million Units)
- Generics in the French Statins Market
- Statins on the French Market, 2007
- Reimbursable Sales of Statins (Régime Générale), 2002-2006 (Million Euros)
- Reimbursable Sales of Statins (Régime Générale), 2002-2006 (%)
- Reimbursable Sales of Statins (Régime Générale), 2002-2006 (Million Units)
- Reimbursable Sales of Statins (Régime Générale), 2002-2006 (%)
- Average Unit Price of Statins (Régime Générale), 2002-2006 (Euros)
- Reimbursable Sales of Statins & Ezetimibe (Régime Générale), 2002-2006 (Million Euros)
- Reimbursable Sales of Statins by Patent Status (Régime Générale), 2005-2006 (Million Euros)
- Reimbursable Sales of Statins by Patent Status (Régime Générale), 2005-2006 (Million Units)
- Pravastatin
- Pravastatin Sales Data (Régime Générale), 2006
- Simvastatin
- Simvastatin Sales Data (Régime Générale), 2005-2006 (000s Euros)
- Simvastatin Sales Data (Régime Générale), 2005-2006 (000s Units)
- Simvastatin + Ezetimibe Sales Data (Régime Générale), 2005-2006 (Million Euros)
- Simvastatin + Ezetimibe Sales Data (Régime Générale), 2005-2006 (Million Units)
- Directory
- Government Organisations
- Generic Trade Association
- Generic Manufacturers
- Italy
- Introduction
- Key Data Projections, 2007-2012
- Healthcare System
- Organisation
- Health Expenditure
- Health Expenditure, 2000-2006 (Million Euros)
- Public Health Expenditure by Type, 2000-2006 (Million Euros)
- Public Health Expenditure by Region & Type, 2006 (Million Euros)
- Private Health Expenditure by Region, 1998-2003 (Million Euros)
- Healthcare Infrastructure
- Hospital Resources
- Inpatient Institutions by Type, 2000-2005
- Inpatient Institutions by Region, 2000-2005
- Hospital Beds by Type, 2005
- Hospital Beds, 1997-2005
- Hospital Beds by Region, 2005
- Hospital Activity
- Hospital Activity, 2000-2004
- Hospital Activity by Sector, 2004
- Public Acute Hospital Activity by Region, 2004
- Private Accredited Acute Hospital Activity by Region, 2004
- Hospital Activity by Diagnosis Group, 2004
- Ambulatory Resources
- Guardia Medica Points by Region, 2005
- Ambulatory & Other Facilities, 2005
- Ambulatory & Other Facilities by Type of Service, 2000-2005
- Ambulatory Activity
- Clinical, Laboratory & Diagnostic Procedures, 2005
- Medical Personnel
- Registered Doctors by Region, 2006
- SSN Personnel, 2000-2005
- Pharmaceutical Market Overview
- Size
- Summary of the Italian Pharmaceutical Market, 2007
- Number of Pharmaceutical Products & Presentations, 2000-2006
- Number of SSN Pharmaceutical Products & Presentations, 2000-2007
- Projections
- Market Projections, 2007-2012
- Local Manufacturers
- Generic Market
- Size
- Net SSN Sales by Patent Status, 2002-2006 (Million Euros)
- Net SSN Sales by Patent Status, 2002-2006 (%)
- Change in Net SSN Sales by Patent Status, 2003-2006 (%)
- Generics Sales as % of Net SSN Sales by Region, 2002-2006
- Per Capita Net SSN Generics Expenditure by Region, 2002-2006 (Euros)
- Net SSN Generics Sales by Region, 2002-2006 (DDD/1,000 Population)
- Generics Sales as % of Net SSN Sales by Region, 2002-2006 (DDD/1,000 Population)
- Gross SSN Generics Sales by Leading Active Ingredient, 2006 (Million Euros)
- Gross SSN Generics Sales by Leading Active Ingredient, 2006 (DDD)
- Projections
- Projected Unbranded Generic Market, 2007-2012
- Outlook
- SWOT Analysis of the Italian Generics Market, 2007
- Domestic Production
- Leading Italian Generic Producers, 2007
- Trade Association
- ASSOGENERICI
- Members of ASSOGENERICI, 2007
- Local Manufacturers
- Angenerico
- Angelini’s Pharmaceutical Companies, 2006
- DOC Generici
- Eurogenerici
- Eurogenerici’s Sales, 2002-2006 (Million Euros)
- Eurogenerici’s Sales, 2002-2006 (%)
- Eugenerici’s Sales as % of Stada’s Sales, 2002-2006 (%)
- Hexan
- Merck Generics Italia
- Merck Generics Italia’s Sales, 2004-2006 (Million Euros)
- Pliva Pharma
- Pliva Italia’s Sales, 2003-2005 (US$ Million)
- Ranbaxy
- ratiopharm Italia
- Sandoz
- Sandoz’s Italian Sales within the Novartis Group, 2004-2005 (Million Euros)
- Teva Pharma Italia
- Teva Pharma Italia’s Production Capabilities, 2006
- Regulatory Environment
- Pricing & Reimbursement
- EU Directive on the Transparency of Pricing & Reimbursement
- Reimbursement
- Intellectual Property
- National Supplementary Protection Certificate
- Leading Active Ingredients with Patents Close to Expiry, 2007
- Directory
- Government Organisations
- Generic Trade Associations
- Generic Manufacturers
- Portugal
- Introduction
- Key Data Projections, 2007-2012
- Healthcare System
- Organisation
- Organic Health Law No/1993
- Health Regions, 1993
- Decree Law No/2001
- Health Expenditure
- Projected Health Expenditure, 2006-2012
- Health Expenditure, 2000-2005 (Million Euros)
- Healthcare Infrastructure
- Hospital Resources
- Public & Private Hospitals, 1990-2005
- Public & Private Hospitals by Region, 2005
- General & Specialty Hospitals by Type, 2005
- Hospital Beds & Operating Rooms, 1990-2005
- Hospital Activity
- Hospital Admissions, 1990-2005
- Hospital Admissions by Region, 2005
- Hospital Admissions by Hospital Type, 2005
- Admissions, Discharges & Patient Days by Hospital Specialty, 2005
- Hospital Consultations by Specialty, 1990-2005 (000s)
- Hospital Consultations by Specialty & Region, 2005 (000s)
- Hospitals Diagnostic Procedures, 2001-2005
- Public & Private Hospitals Therapeutic Procedures, 2005
- Outpatient Resources
- Outpatient Health Centres, Sub-Centres & Beds, 1990-2005
- Outpatient Activity
- Outpatient Admissions & Days, 1990-2005
- Outpatient Admissions & Days by Region, 2005
- Outpatient Consultations by Specialty, 1990-2005 (000s)
- Medical Personnel
- Pharmaceutical Market Overview
- Size
- Summary of the Portuguese Pharmaceutical Market at Retail Prices, 2007
- Projections
- Market Projections, 2007-2012
- Local manufacturers
- INFARMED’s Listed National Manufacturers, 2007
- Generic Market
- Size
- Generics Pharmacy Sales by Value & Volume, 2003-2006
- Generics Pharmacy Sales by Month, 2003-2006 (Million Euros)
- Generics Pharmacy Sales by Month, 2003-2006 (000 Units)
- Generics as a Percentage of the Pharmacy Sector by Volume, 2003-2006
- Generics Pharmacy Sales by Therapeutic Area, 2006 (Million Euros)
- Generics Pharmacy Sales by Therapeutic Area, 2006 (Million Units)
- Generics Pharmacy Sales by Leading Active Ingredient, 2006 (Million Euros)
- Generics Pharmacy Sales by Leading Active Ingredient, 2006 (Million Units)
- Projections
- Projected Generics Market, 2007-2012
- Outlook
- SWOT
- SWOT Analysis of the Portuguese Generics Market, 2007
- Trade Association
- APOGEN
- Members of APOGEN, 2007
- Domestic Production
- Leading Portuguese Generic Producers, 2007
- Leading Generic Producers in the Pharmacy Sector, 2005 (%)
- Local Manufacturers
- Actavis
- Alter
- Bluepharma
- Ciclum Farma
- Ciclum Farma’s Sales, 2005-2006 (Million Euros)
- Generis
- Germed
- Hovione
- Labesfal
- Medinfar
- Merck Genéricos
- Ranbaxy
- ratiopharm
- Sandoz
- Tecnimede
- Tecnimede’s Financial Indicators, 2003-2007
- Tecnimede’s Employees by Company, 2007
- ToLife
- Winthrop
- Regulatory Environment
- Registration
- Market Authorisations of Generic Medicines in the Pharmacy Sector, 2004-2007
- Change in Market Authorisations of Generic Medicines in the Pharmacy Sector, 2005-2007 (%)
- Market Authorisations of Generic Presentations, 2004-2007
- Change in Market Authorisations of Generic Presentations, 2005-2007 (%)
- Pricing & Reimbursement
- Generics Presentations by Reimbursement Status & Price Range, 2005
- Reimbursement
- EU Directive on the Transparency of Pricing & Reimbursement
- Reimbursements
- Generic Medicines by Reimbursement & Prescription Status, 2005
- Generic Presentations by Reimbursement & Prescription Status, 2005
- Generic Medicines & Presentations by Reimbursement Level, 2005
- Generic Presentations by Reimbursement Level & Therapeutic Group, 2005
- Intellectual Property
- European Supplementary Protection Certificate
- Organon Commences Tibolone Patent Infringement Litigation in Portugal
- Directory
- Government Organisations
- Generic Trade Association
- Generic Manufacturers
- Spain
- Introduction
- Key Data, 2007-2012
- Healthcare System
- Organisation
- Health Cohesion & Quality Law
- Health Expenditure
- Projected Health Expenditure, 2007-2012
- Healthcare Infrastructure
- Hospital Resources
- Hospitals by Provision & Region, 2006
- Hospitals by Provision & Specialty, 2006
- Hospitals, 1985-2006
- Hospital Beds by Provision & Region, 2006
- Hospital Beds by Provision & Specialty, 2006
- Hospital Beds, 1985-2006
- Hospital Activity
- Hospital Activity by Provision, 2005
- Hospital Activity by Specialty, 2005
- Hospital Discharges by Hospital Type & Specialty, 2005
- Hospital Discharges, 1994-2005
- Ambulatory Resources
- Primary Care Consultations, 1994 & 2003
- Medical Personnel
- Registered Medical Personnel, 2000-2006
- Practising Medical Personnel, 2006
- Pharmaceutical Market Overview
- Size
- Summary of the Spanish Pharmaceutical Market, 2007
- Projections
- Market Projections, 2007-2012
- Local Manufacturers
- Leading Pharmaceutical Companies in Spain, 2006
- Generic Market
- Size
- Generics Pharmacy Sales by Value & Volume, 2002-2006
- Pharmacy Sales Value & Volume by Patent Status, 2006
- SNS Pharmaceutical Sales by Patent Status, 2000-2005 (Million Euros)
- SNS Pharmaceutical Sales by Patent Status, 2000-2005 (%)
- Change in SNS Pharmaceutical Sales by Patent Status, 2000-2005 (%)
- SNS Pharmaceutical Sales by Patent Status, 2000-2005 (Million Units)
- SNS Pharmaceutical Sales by Patent Status, 2000-2005 (%)
- Change in SNS Pharmaceutical Sales by Patent Status, 2000-2005 (%)
- SNS Prescription Cost by Patent Status, 2000-2005 (Euros)
- Projections
- Projected Generics Market, 2007-2012
- Outlook
- Biosimilars’ Substitution, Not a Viable Option in Spain
- Regional INN Prescribing
- Regional Generic Penetration
- The II Iberian Simposium on Generics
- Findings of the Study on Generics Perception, October 2005
- SWOT
- SWOT Analysis of the Spanish Generics Market, 2007
- Trade Association
- AESEG
- Members of AESEG, 2007
- Local Manufacturers
- Leading Spanish Generic Producers, 2007
- Companies with Generics in the Market, January 2007
- Number of Companies with Generics in the SNS Market, 2000-2006
- Companies by Number of Generics in the SNS Market, 2000-2006
- Companies by Number of Generics in the SNS Market, 2006
- Adamed
- Alter
- Alter’s Financial Indicators, 2005-2006
- Barr
- Cantabria Pharma
- Cinfa
- Combino Pharm
- DOMAC
- Dr Reddy’s
- Kern Pharma
- Mabo-Farma
- Merck
- Normon
- Normon’s Financial Indicators, 1997-2006
- Pharmagenus
- Ranbaxy
- Ranbaxy Spain’s Sales, 2004-2006 (US$ Million)
- ratiopharm
- Sandoz
- Novartis España’s Sales by Division, 2000-2005 (Million Euros)
- Novartis España’s Employees by Division, 2000-2005
- Sandoz’s Leading Generics, 2005
- Stada
- Laboratorio Stada’s Sales, 2003-2006 (Million Euros)
- Teva
- Regulatory Environment
- Registration
- Active Ingredients & Presentations of Generic Medicines, 2000-2006
- Presentations by Patent Status, 2006
- Presentations of Generic Medicines by Administration Type, 2000-2006
- Presentations of Generic Medicines by Administration Type, 2000-2006 (%)
- Active Ingredients & Presentations of Generic Medicines by Therapeutic Area, 2006
- Active Ingredients with the Highest Number of Generic Presentations, 2000-2006
- Active Ingredients with the Highest Number of Presentations by Patent Status, 2006
- Pricing & Reimbursement
- Co-Payments
- Co-Payments, 2006
- RPS Analysis
- SNS Pharmaceutical Sales by the Reference Price System, 2005 (%)
- Generic Pricing
- Retail Prices of Presentations of Generic Medicines by Type, 2002-2006 (Euros)
- Intellectual property
- European Supplementary Protection Certificate
- Directory
- Government Organisations
- Generic Trade Association
- Generic Manufacturers
AbstractThe four EU countries analysed in this report - France, Italy, Portugal, Spain - are expected to deliver significant double digit growth over the next 5 years and present stable, regulated operating environments with excellent prospects. Key Areas Addressed:
- 5-year market forecasts to 2012 for the pharmaceutical and generic drug markets
- Analysis of market trends and outlook of key developments
- Domestic production and review of leading companies
- Regulatory environment
- Health provision and plans
THIS REPORT ANSWERS KEY QUESTIONS
- Which therapy sector accounted for the greatest part of the Spanish generics market in 2006?
- What measures are in place to reduce generic prices in Portugal?
- How might developments in the French reference pricing system affect the generics market?
- What developments with supplementary protection certificates will positively affect the Italian generics market after 2010?
- What are the 8 leading active ingredients to lose patent protection in Italy in 2007?
- How has generic pravastatin fared in the French statin market against simvastatin?
For a complete review of the market, prospects and competitive environment in these important generic drugs markets make sure you read this unique report.
Get Full Details About This Report >>
|
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
